what can you eat while taking semaglutide Top 5 Foods to Avoid Ozempic π½οΈ Curious about what to
Description
Patients who combine GLP-1 therapy with CGM monitoring tend to make smarter lifestyle choices and see better outcomes
Quiet the cravings, support new habits
Purpose of Review This review explores the rationale and available evidence behind incretin-based therapies for metabolic dysfunction-associated steatotic disease (MASLD) and metabolic-associated steatohepatitis (MASH), focusing on glucagon-like peptide 1 (GLP-1) and glucagon (GCG) receptor dual agonists (GLP-1/GCG RAs)
What is the potential of each market
Beyond cost, genetic factors in peptide pathways may help contextualize individual treatment readiness
